{"classes":[{"categories":[{"measurements":[{"comment":"There were too few events to provide an estimable UL of the CI.","groupId":"OG000","lowerLimit":"1.3","upperLimit":"NA","value":"2.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"DoR is defined as the time from the first documented evidence of CR (disappearance of all extra nodal lesions. Any pathological lymph node must be less than 10 mm in the short axis) or PR (at least a 30% decrease in the sum of the diameters of target lesions) until PD or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions, or the worsening of non-target lesions significant enough to require study treatment discontinuation. DoR data were summarized per RECIST, Version 1.1Only those participants with confirmed response (CR and PR) were analyzed. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles). NA indicates data was not available.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to chemotherapy and who did not receive subsequent anti-cancer therapy after discontinuing chemotherapy were allowed to cross-over to Trametinib and received 2 mg tablet once daily until disease progression, death or withdrawal.","id":"OG000","title":"Cross-over From Chemotherapy to Trametinib"}],"paramType":"MEDIAN","populationDescription":"Cross-over Population","reportingStatus":"POSTED","timeFrame":"Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)","title":"DoR for All Responders (CR or PR) Following Cross-over to Trametinib as Assessed by the Investigator","type":"SECONDARY","unitOfMeasure":"Months"}